EPMA Journal

, Volume 10, Issue 3, pp 239–248 | Cite as

The potential role of angiopoietin-like protein-8 in type 2 diabetes mellitus: a possibility for predictive diagnosis and targeted preventive measures?

  • Yasmine Amr IssaEmail author
  • Samar Samy Abd ElHafeez
  • Noha Gaber Amin



Previous studies showed altered angiopoietin-like protein-8 (ANGPTL-8) circulating levels in type 2 diabetes mellitus (DM). Whether or not the alteration in ANGPTL-8 level can be a predictive maker for increased DM risk remains unclear.


Investigating possible role of ANGPTL-8 as a risk predictor of type2 DM, in addition to a set of factors likely to affect ANGPTL-8 level.


One hundred recently diagnosed persons with type 2 DM and 100 sex- and age-matched healthy controls were enrolled. Exclusion criteria included type 1 DM, acute infections, history of chronic kidney disease, malignancy, and blood loss or transfusion. Serum levels of ANGPTL-8, blood pressure, weight, height, glycosylated hemoglobin (HbA1c), fasting blood glucose, cystatin C, lipid profile, liver, and kidney function tests were assessed. The independent relationship between DM and ANGPTL-8 was tested in the unadjusted and multiple-adjusted regression models.


Serum ANGPTL-8 levels showed significant elevation among persons with vs. without DM (p = 0.006), positive correlation with HbA1c (p < 0.001), and negative correlation with estimated GFR (eGFR) (p = 0.003) but no significant correlation to fasting glucose level. In the unadjusted model, patients in the third tertile of ANGPTL-8 had 4 times risk of DM (OR 4.03; 95% CI = 1.37–11.84). Data adjustment for cardiovascular diseases, smoking, body mass index, systolic blood pressure, alanine transaminase (ALT), and low-density lipoprotein (LDL) increased the direct relationship between ANGPTL-8 and DM (OR 6.26; 95% CI = 1.21–32.50). However, the risk significantly decreased after adjustment of Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR creatinine-cystatin (OR 2.17; 95% CI = 0.10–49.84).


This study highlights a possible predictive role of ANGPTL-8 in diabetic complications, particularly nephropathy. Larger prognostic studies are needed to validate the cause-effect relationship between ANGPTL-8 and deteriorated kidney functions.


Type 2 diabetes mellitus ANGPTL-8 Predictive preventive personalized medicine Renal function Adipokine Hepatokine 



The authors would like to acknowledge the efforts of the medical postgraduate student Mohamed Abd Allah ElKelany, in data collection and entry.

Authors’ contribution

All authors contributed to the conception of idea, study design, laboratory investigations, interpretation of results, writing and revising the manuscript, providing intellectual content of critical importance to the work described, and final approval of the version to be published. In addition, Dr. Yasmine Amr Issa carried out all laboratory investigations, Dr. Samar Samy Abd ElHafeez was responsible for statistical analysis, and Dr. Noha Gaber Amin executed the recruitment, examination, and data collection of patients. All authors are also accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval for human studies

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Alexandria Faculty of Medicine Ethics of the research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all participants in this study.


  1. 1.
    Duarte AA, Mohsin S, Golubnitschaja O. Diabetes care in figures: current pitfalls and future scenario. EPMA J. 2018;9(2):125–31.CrossRefGoogle Scholar
  2. 2.
    International diabetes federation. Diabetes atlas, 8th edn. 2017. Available at : Accessed 15 June 2019.
  3. 3.
    Golubnitschaja O, Baban B, Boniolo G, et al. Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016. EPMA J. 2016;7:23.CrossRefGoogle Scholar
  4. 4.
    Golubnitschaja O. Advanced diabetes care: three levels of prediction, prevention & personalized treatment. Curr Diabetes Rev. 2010;6(1):42–51.CrossRefGoogle Scholar
  5. 5.
    Suwannaphant K, Laohasiriwong W, Puttanapong N, et al. Association between socioeconomic status and diabetes mellitus: the National Socioeconomics Survey, 2010 and 2012. J Clin Diagn Res. 2017;11(7):LC18–22.Google Scholar
  6. 6.
    Ge S, Xu X, Zhang J, et al. Suboptimal health status as an independent risk factor for type 2 diabetes mellitus in a community-based cohort: the China suboptimal health cohort study. EPMA J. 2019;10(1):65–72.CrossRefGoogle Scholar
  7. 7.
    Soliman N, El-Shabrawi M, Omar S. DNA fragmentation damage as a predictive marker for diabetic nephropathy in type II diabetes mellitus. J Endocrinol Metab Diabetes S Afr. 2018;23(2):32–5.Google Scholar
  8. 8.
    Saadeldin MK, Elshaer SS, Emara IA, et al. Serum sclerostin and irisin as predictive markers for atherosclerosis in Egyptian type II diabetic female patients: a case control study. PLoS One. 2018;13(11):e0206761.CrossRefGoogle Scholar
  9. 9.
    Lee H, Park T, Kim B. Metabolic markers predictive of prediabetes in the Korean population. Diabetes. 2018;67(Supplement 1).
  10. 10.
    Golubnitschaja O, Costigliola V. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012;3(1):14.CrossRefGoogle Scholar
  11. 11.
    Gupta M, Singh JP. Correlation of microalbuminuria with glycosylated haemoglobin in patients of diabetes having nephropathy. Int J Adv Med. 2017;4(3):805–8.CrossRefGoogle Scholar
  12. 12.
    Sena CM, Bento CF, Pereira P, et al. Diabetes mellitus: new challenges and innovative therapies. EPMA J. 2010;1(1):138–63.CrossRefGoogle Scholar
  13. 13.
    Golubnitschaja O, Costigliola V. EPMA summit 2014 under the auspices of the presidency of Italy in the EU: professional statements. EPMA J. 2015;6(1):4.CrossRefGoogle Scholar
  14. 14.
    Ren G, Kim JY, Smas CM. Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism. Am J Physiol Endocrinol Metab. 2012;303(3):E334–51.CrossRefGoogle Scholar
  15. 15.
    Quagliarini F, Wang Y, Kozlitina J, et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A. 2012;109(48):19751–6.CrossRefGoogle Scholar
  16. 16.
    Zhang R. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun. 2012;424(4):786–92.CrossRefGoogle Scholar
  17. 17.
    Fu Z, Yao F, Abou-Samra AB, et al. Lipasin, thermoregulated in brown fat, is a novel but atypical member of the angiopoietin-like protein family. Biochem Biophys Res Commun. 2013;430(3):1126–31.CrossRefGoogle Scholar
  18. 18.
    Yi P, Park JS, Melton DA. Betatrophin: a hormone that controls pancreatic beta cell proliferation. Cell. 2013;153(4):747–58.CrossRefGoogle Scholar
  19. 19.
    Luo M, Peng D. ANGPTL8: an important regulator in metabolic disorders. Front Endocrinol (Lausanne). 2018;9:169.CrossRefGoogle Scholar
  20. 20.
    Maurer L, Schwarz F, Fischer-Rosinsky A, et al. Renal function is independently associated with circulating betatrophin. PLoS One. 2017;12(3):e0173197.CrossRefGoogle Scholar
  21. 21.
    Zhang R, Abou-Samra AB. Emerging roles of lipasin as a critical lipid regulator. Biochem Biophys Res Commun. 2013;432(3):401–5.CrossRefGoogle Scholar
  22. 22.
    Yi P, Park JS, Melton DA. Retraction notice to: betatrophin: a hormone that controls pancreatic beta cell proliferation. Cell. 2017;168(1–2):326.CrossRefGoogle Scholar
  23. 23.
    Li S, Liu D, Li L, et al. Circulating betatrophin in patients with type 2 diabetes: a meta-analysis. J Diabetes Res. 2016;2016:6194750.Google Scholar
  24. 24.
    Leiherer A, Muendlein A, Geiger K, et al. Betatrophin is associated with type 2 diabetes and markers of insulin resistance. Diabetes. 2018;67(Supplement 1).
  25. 25.
    Gomez-Ambrosi J, Pascual E, Catalan V, et al. Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes. J Clin Endocrinol Metab. 2014;99(10):E2004–9.CrossRefGoogle Scholar
  26. 26.
    Gokulakrishnan K, Manokaran K, Pandey GK, et al. Relationship of betatrophin with youth onset type 2 diabetes among Asian Indians. Diabetes Res Clin Pract. 2015;109(1):71–6.CrossRefGoogle Scholar
  27. 27.
    Fenzl A, Itariu BK, Kosi L, et al. Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals. Diabetologia. 2014;57(6):1204–8.CrossRefGoogle Scholar
  28. 28.
    Espes D, Lau J, Carlsson PO. Increased circulating levels of betatrophin in individuals with long-standing type 1 diabetes. Diabetologia. 2014;57(1):50–3.CrossRefGoogle Scholar
  29. 29.
    Fu Z, Berhane F, Fite A, et al. Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity. Sci Rep. 2014;4:5013.CrossRefGoogle Scholar
  30. 30.
    Zhang R. Abou-Samra AB. A dual role of lipasin (betatrophin) in lipid metabolism and glucose homeostasis: consensus and controversy. Cardiovasc Diabetol. 2014;13:133.CrossRefGoogle Scholar
  31. 31.
    Hu H, Sun W, Yu S, et al. Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients. Diabetes Care. 2014;37(10):2718–22.CrossRefGoogle Scholar
  32. 32.
    Tuhan H, Abaci A, Anik A, et al. Circulating betatrophin concentration is negatively correlated with insulin resistance in obese children and adolescents. Diabetes Res Clin Pract. 2016;114:37–42.CrossRefGoogle Scholar
  33. 33.
    Battal F, Turkon H, Aylanc N, et al. Investigation of blood Betatrophin levels in obese children with non-alcoholic fatty liver disease. Pediatr Gastroenterol Hepatol Nutr. 2018;21(2):111–7.CrossRefGoogle Scholar
  34. 34.
    Ebert T, Kralisch S, Hoffmann A, et al. Circulating angiopoietin-like protein 8 is independently associated with fasting plasma glucose and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2014;99(12):E2510–7.CrossRefGoogle Scholar
  35. 35.
    Chen CC, Susanto H, Chuang WH, et al. Higher serum betatrophin level in type 2 diabetes subjects is associated with urinary albumin excretion and renal function. Cardiovasc Diabetol. 2016;15:3.CrossRefGoogle Scholar
  36. 36.
    Cioms W. International ethical guidelines for epidemiological studies. Geneva. 2009.Google Scholar
  37. 37.
    American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2017;39(Suppl 1):S13–22.Google Scholar
  38. 38.
    Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2013;367(1):20–9.CrossRefGoogle Scholar
  39. 39.
    Grambsch PM, Therneau TM, Fleming TR. Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics. 1995;51(4):1469–82.CrossRefGoogle Scholar
  40. 40.
    Pan R, Zhang H, Yu S, et al. Betatrophin for diagnosis and prognosis of mothers with gestational diabetes mellitus. J Int Med Res. 2019;47(2):710–7.CrossRefGoogle Scholar
  41. 41.
    Abu-Farha M, Abubaker J, Al-Khairi I, et al. Higher plasma betatrophin/ANGPTL8 level in type 2 diabetes subjects does not correlate with blood glucose or insulin resistance. Sci Rep. 2015;5:10949.CrossRefGoogle Scholar
  42. 42.
    Lee SH, Rhee M, Kwon HS, et al. Serum betatrophin concentrations and the risk of incident diabetes: a nested case-control study from Chungju metabolic disease cohort. Diabetes Metab J. 2018;42(1):53–62.CrossRefGoogle Scholar
  43. 43.
    Fortwaengler K, Parkin CG, Neeser K, et al. Description of a new predictive modeling approach that correlates the risk and associated cost of well-defined diabetes-related complications with changes in glycated hemoglobin (HbA1c). J Diabetes Sci Technol. 2017;11(2):315–23.CrossRefGoogle Scholar
  44. 44.
    Penno G, Solini A, Bonora E, et al. HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Diabetes Care. 2013;36(8):2301–10.CrossRefGoogle Scholar
  45. 45.
    Guo K, Lu J, Yu H, et al. Serum betatrophin concentrations are significantly increased in overweight but not in obese or type 2 diabetic individuals. Obesity (Silver Spring). 2015;23(4):793–7.CrossRefGoogle Scholar
  46. 46.
    Yamada H, Saito T, Aoki A, et al. Circulating betatrophin is elevated in patients with type 1 and type 2 diabetes. Endocr J. 2015;62(5):417–21.CrossRefGoogle Scholar
  47. 47.
    Ebert T, Kralisch S, Wurst U, et al. Betatrophin levels are increased in women with gestational diabetes mellitus compared to healthy pregnant controls. Eur J Endocrinol. 2015;173(1):1–7.CrossRefGoogle Scholar
  48. 48.
    Mahmood D, Makoveichuk E, Nilsson S, et al. Response of angiopoietin-like proteins 3 and 4 to hemodialysis. Int J Artif Organs. 2014;37(1):13–20.CrossRefGoogle Scholar
  49. 49.
    Pfau D, Bachmann A, Lossner U, et al. Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care. 2010;33(1):171–3.CrossRefGoogle Scholar
  50. 50.
    Stein S, Bachmann A, Lossner U, et al. Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care. 2009;32(1):126–8.CrossRefGoogle Scholar
  51. 51.
    Merabet E, Dagogo-Jack S, Coyne DW, et al. Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab. 1997;82(3):847–50.Google Scholar
  52. 52.
    Golubnitschaja O. Time for new guidelines in advanced diabetes care: paradigm change from delayed interventional approach to predictive, preventive & personalized medicine. EPMA J. 2010;1(1):3–12.CrossRefGoogle Scholar

Copyright information

© European Association for Predictive, Preventive and Personalised Medicine (EPMA) 2019

Authors and Affiliations

  1. 1.Department of Medical Biochemistry, Alexandria Faculty of MedicineUniversity of AlexandriaAlexandriaEgypt
  2. 2.Department of Epidemiology, High Institute of Public HealthUniversity of AlexandriaAlexandriaEgypt
  3. 3.Department of Internal Medicine, Clinical Diabetes and Metabolism unit, Alexandria Faculty of MedicineUniversity of AlexandriaAlexandriaEgypt

Personalised recommendations